Editorial Videos

Aradigm Health CEO Will Shrank discusses the shift in value-based care models for cell and gene therapies.

Will Shrank, Aradigm Health’s CEO, discusses the importance of transparency in healthcare payments to build trust and reduce waste.

Aradigm CEO Will Shrank discusses the significant challenge payers face in predicting and managing the costs of cell and gene therapies due to their volatility and unpredictability.

In the final part of his interview, Jeff Golfman discusses how data-driven supply chain mapping and collaborative procurement models can gain traction as companies move beyond cost-focused sourcing to strengthen resilience.

Will Shrank, CEO of Aradigm Health, discusses the fragmented payment and delivery system and its impact on cell & gene therapies.

Jessica Lovett, VP of commercial strategy and innovation at Innomar, discusses the importance of meeting the needs of everyone at the table.

In the second part of his interview, Jeff Golfman notes how shelf-life constraints and shipping delays heighten drug shortage risk, prompting calls for diversified sourcing and larger inventory buffers.

In the final part of her interview, Plesnarski notes how market access strategies evolve into core launch drivers as IRA timelines, pricing pressures, and digital adherence tools reshape how companies maximize value.

Dr. Stella Vnook explains how pharma pricing is likely to be impacted by various regulatory actions, such as MFN.

In this exclusive video interview at Assembia 2026, Kim Plesnarski touches on how digital tools reshape patient access programs as real-time data and EMR integration drive more personalized, workflow-embedded support strategies.

Dr. Stella Vnook explains how US pricing regulations, such as MFN and the IRA, are forcing pharma companies to adjust strategies in international markets.

Tommy Bramley, SVP of global consulting at Cencora, discusses how broadening acceptance of RWE has a broad impact on launch strategies.

Dr. Stella Vnook discusses how pricing transparency and VBC might have a more positive impact than MFN and other pricing regulations.

Maher Masoud, CEO of MaxCyte, explains how the current environment is impacting the entrepreneurial spirit in the pharmaceutical industry.

MaxCyte CEO Maher Masoud discusses how new treatment methods are providing greater control of the therapy’s safety profile.

Maher Masoud, CEO of MaxCyte, discusses the need for developers to come together with platforms.

Samsung Bioepis’ Thomas Newcomer explains the reasons why biosimilar developers are or are not feeling confident about the consistency of the US market in the coming years.

Imran Khan, Md, PhD, Vice President of U.S. medical affairs for hematology, oncologist, Johnson & Johnson, discusses why J&J was chose for the CNPV program and it's experience during the process.

The IRA and MFN are affecting decisions made all throughout the entire drug development process.

Imran Khan, Md, PhD, Vice President of U.S. medical affairs for hematology, oncologist, Johnson & Johnson, notes select influences of how the Phase III clinical testing was conducted.

Imran Khan, Md, PhD, Vice President of U.S. medical affairs for hematology, oncologist, Johnson & Johnson, touched on Tecvayli plus Darzalex Faspro reducing the risk of disease progression or death by 83%, and what that signals for patients.

Thomas Newcomer of Samsung Bioepis discusses how certain classes of drugs don’t have enough biosimilars in development and the impact that this can have in the coming years.

The Phenomix CEO discusses recent data that suggests that patients may not be prepared for the side effects and unexpected costs of GLP-1s.

Phenomix CEO Mark Bagnall discusses the effectiveness of GLP-1s and how obesity impacts different patients in a variety of complex ways.

Christopher Locher, PhD, CEO, Versatope Therapeutics, Inc., discusses how emerging vaccine platforms are advancing the pursuit of a universal influenza vaccine, while highlighting the scientific, regulatory, and economic barriers that continue to shape its path to reality.

MFN policies are likely to impact more than pricing, and drug companies may alter drug launch plans in the future.

Yerem Yeghiazarians, MD, explains how understanding how various cells react differently to stress impacts how damaged cells may potentially be treated.

Drug pricing restrictions are likely to impact drug launches, especially for medications expected to be sought after by Medicare patients.